Open AccessModeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda
Author(s) -
Erika Wallender,
Nan Zhang,
Melissa D. Conrad,
Abel Kakuru,
Mary Muhindo,
Patrick K. Tumwebaze,
Richard Kajubi,
Daniel J. Mota,
Jennifer Legac,
Prasanna Jagannathan,
Diane V. Havlir,
Moses R. Kamya,
Grant Dorsey,
Francesca Aweeka,
Philip J. Rosenthal,
Rada Savic
Publication year - 2018
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01393-18
Subject(s) - piperaquine , dihydroartemisinin , dosing , medicine , pharmacology , drug , malaria , parasitemia , drug resistance , artemisinin , pregnancy , plasmodium falciparum , biology , immunology , genetics , microbiology and biotechnology
Dihydroartemisinin-piperaquine (DHA-PQ) is under study for intermittent preventive treatment during pregnancy (IPTp), but it may accelerate selection for drug resistance. Understanding the relationships between piperaquine concentration, prevention of parasitemia, and selection for decreased drug sensitivity can inform control policies and optimization of DHA-PQ dosing.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom